7,774 press releases indexed under healthcare.
The 2025 IDEA Fitness Leader of the Year and MSN's #1 Top Health Voice of 2026 joins Glo as its September Featured Guest Teacher HONOLULU, Sept. 14, 2026 /PRNewswire/ -- Dr. Desi Bartlett, Ed.D., founder of The BodyMind Workout™, today announced a new partnership with Glo, the premier...
Ambassador Deborah Birx Announces New Data-Driven Framework Evaluating 16,239 Hospitals Across 65 Countries NEW YORK, Sept. 14, 2026 /PRNewswire/ -- At today's 15TH annual C3 US NYC Davos of Healthcare™ Summit, held alongside the United Nations General Assembly, Davos Healthcare™...
Working With Clients From All Walks of Life, From Fortune 500 Companies to Respected Experts and Global Brands, VEW Media Has Spent 25 Years Finding and Telling Stories That Matter NORTH ATTLEBORO, MA - September 14, 2026 ( NEWMEDIAWIRE ) - VEW Media, the PR agency that has been helping clients get ViEWed globally since 2001, is celebrating its 25 year of business. Over the past quarter-century, VEW Media has represented an extraordinarily diverse roster of clients, including consumer brands, authors, physicians, technology innovators, and Fortune 500 companies, helping each turn what makes them distinctive into stories that resonate with national, international, and industry media. It is celebrating its 25th anniversary in September 2026. Since opening in 2001, the agency has helped compa
Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program Advances GeoVax’s Strategy to Expand and Diversify MVA Vaccine Supply ATLANTA, GA - September 14, 2026 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high consequence infectious diseases and solid tumor cancers, today announced that it has entered into a Memorandum of Agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) providing GeoVax access to clinical trial sample testing services through the CEPI Centralised Laboratory Network in support of its planned pivotal GEO-MVA Phase 3 immune-bridging study. The agreement represents an important step in the continued development of GEO-MVA, GeoVax’s MVA-based vaccine ca
(PR-inside.com) SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration's ("FDA") public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," being held today, Monday, September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland. Dr. Langford is among a limited group ..
New data show 97% opioid abstinence rates among long-term patients as statewide overdose deaths begin to decline. HELENA, Mont., Sept. 14, 2026 /PRNewswire-PRWeb/ -- Ideal Option, a national leader in outpatient medication-assisted treatment (MAT) for addiction to opioids, stimulants and...
Dr Charles Garrison, an experienced pathologist, biotechnology entrepreneur, and life sciences investor will advise MVT on scientific and medical development as new Scientific Advisory Board member. [PR.com]
TARRYTOWN, N.Y., Sept. 14, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing first-in-class peptide therapeutics targeting the underlying oncogenic and immune mechanisms driving cancer and pre-cancerous disease, today...
Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal...
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA)...
IND clearance further expands development of C-CAR168 across chronic autoimmune diseases with significant unmet medical need ROCKVILLE, Md. and SHANGHAI, Sept. 14, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company...